Monoclonal Antibodies in Cancer Therapy

Abstract

In recent years, there have been significant advancements in cancer treatment, particularly with the use of Monoclonal Antibodies (mAbs). These targeted therapies have shown promise in managing different types of cancer with fewer side effects due to their high specificity. They have become a predominant category of newly developed drugs. Monoclonal antibodies offer diverse mechanisms of action and can directly target cancer cells while also boosting long-lasting anti-tumor immune responses. This versatility has led to the development of innovative cancer treatment strategies. The use of monoclonal antibody drugs has grown rapidly, with FDA approval for various diseases, including cancer, autoimmune disorders, metabolic conditions, and infectious diseases. As of December 2019, 79 therapeutic mAbs have been approved by the FDA, but there is still room for expansion in this field.